9月21日，阿里健康盘中下跌5.38%，报2.9港元/股，成交额1.28亿港元。消息面上，中金当日发布研报，基于SOTP估值法将阿里健康目标价大幅下调30.8%至4.5港元，同时下调2027FY及2028FY non-GAAP净利润预测6.6%/5.8%至21.78亿元和24.21亿元，主要原因包括保健品类表现波动、保健品行业监管带来情绪压制，以及医学AI投入节奏不确定性。
此外，公司近期利空因素叠加：9月14日被调出港交所科技100指数，新任董事长余涌刚于9月11日接替沈涤凡上任，远场电商增速放缓及AI商业化前景待验证等问题持续压制市场情绪。UBS此前亦连续减持，好仓比例降至7.96%。多重负面因素共振下，股价承压明显。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.